The molecular mechanisms of traditional Chinese medicine ZHENG syndromes on pancreatic tumor growth

Integrative Cancer Therapies

Volumn 9, Issue 3, 2010, Pages 291-297

  Dai, Hai Yan ^a   Peng Wang, ^a   Feng, Lan Yun ^a   Liu, Lu Ming ^a   Meng, Zhi Qiang ^a   Zhu, Xiao Yan ^a   Kun Wang, ^a   Hua, Yong Qiang ^a   Mao, Yi Xiang ^a   Chen, Lian Yu ^a   Chen, Zhen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CCR5 CCL5 CCL4; CXCR4 SDF 1; pancreatic cancer; personalized therapy; Pi Xu; Shi Re; traditional Chinese medicine; tumor micro environment; ZHENG

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; RANTES; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CHINESE HERB; CHINESE MEDICINE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CXCL12; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PANCREAS; PANCREATIC NEOPLASMS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 78649913431     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410373922     Document Type: Article

References (30)

1. Dobos GJ, Tan L., Cohen MH, et al. Are national quality standards for traditional Chinese herbal medicine sufficient? Current governmental regulations for traditional Chinese herbal medicine in certain Western countries and China as the Eastern origin country. Complement Ther Med. 2005 ; 13: 183-190.
2. Molassiotis A., Fernandez-Ortega P., Pud D., et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005 ; 16: 655-663. (Pubitemid 40613334)
3. Kong Y., Jiang Q. The discussion of treatment based on syndrome differentiation and personalized therapy of cancer. Lishizhen Med Materia Medica Res. 2009 ; 20: 752-753.
4. Xu L., Sun D. -Z, Liu L., Wei P. -K. Expression of tumor metastasis-related gene protein in the same syndromic classification of gastric carcinoma on traditional Chinese medicine. World Chin J Digestol. 2004 ; 12: 2782-2787.
5. You-xin Y., Hong-xia Y., Er-qing D., et al. Relativity study of pathology variation and syndrome types of TCM on precancerous lesion of chronic atrophic gastritis patients. J Tianjin Univ Tradit Chin Med. 2006 ; 25: 207-209.
6. Fan Z., Liang F., Li Q. Analysis of TCM treatment of advanced pancreatic cancer. Liaoning J Tradit Chin Med. 2008 ; 35: 679-681.
7. Liu L., Song M. Experience of Yuerrxin About TCM Treatment of Liver Cancer. Beijing, China: People's Medical Publishing House ; 2004 :177.
8. Lu G., Shaoxian L. Establishment and evaluation of animal models of Spleen-stomach Damp-heat syndrome. J Guangzhou Univ Tradit Chin Med. 2005 ; 22: 231-235.
9. Deprez RHL, Fijnvandraat AC, Ruijter JM, Moorman AFM. Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal Biochem. 2002 ; 307: 63-69.
10. Dhillon N., Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 ; 14: 4491-4499.
11. Ryan JL, Marsh L., Ling M., et al. Curcumin improves radiation dermatitis in breast cancer patients: interim analysis of randomized, double-blind, placebo-controlled clinical trial. J Invest Dermatol. 2009 ; 129: S51 - S51.
12. Xue Y., Wen-Chao L. Treatment based on syndrome differentiation and molecular targeted therapy of cancer medicine and philosophy. Clin Decis Making Forum Ed. 2009 ; 30: 68-69.
13. Gu CongDe. The Yellow Emperor's Inner Classic, Essential Questions [Chinese name: Huangdi Neijing, Suwen]. 1956.
14. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889 ; 1: 571-573.
15. Vaday GG, Peehl DM, Kadam PA, Lawrence DM Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006 ; 66: 124-134.
16. Luker KE, Luker GD Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006 ; 238: 30-41.
17. Kucia M., Reca R., Miekus K., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005 ; 23: 879-894.
18. Rollins BJ Inflammatory chemokines in cancer growth and progression. Eur J Cancer. 2006 ; 42: 760-767.
19. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001 ; 410: 50-56.
20. Koshiba T., Hosotani R., Miyamoto Y., et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000 ; 6: 3530-3535.
21. Wehler T., Wolfert F., Schimanski CC, et al. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep. 2006 ; 16: 1159-1164.
22. Soria G., Ben-Baruch A. The CCL5/CCR5 axis in cancer. In: Fulton AM, ed. Chemokine Receptors in Cancer. New York, NY: Humana Press ; 2009: 109-130.
23. Mueller A., Strange PG Mechanisms of internalization and recycling of the chemokine receptor, CCR5. Eur J Biochem. 2004 ; 271: 243-252.
24. Trentin L., Miorin M., Facco M., et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol. 2007 ; 138: 594-602.
25. Manes S., Mira E., Colomer R., et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med. 2003 ; 198: 1381-1389.
26. Tan MCB, Goedegebuure PS, Belt BA, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009 ; 182: 1746-1755.
27. Niwa Y., Akamatsu H., Niwa H., Sumi H., Ozaki Y., Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001 ; 7: 285-289.
28. Bieche I., Lerebours F., Tozlu S., Espie M., Marty M., Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004 ; 10: 6789-6795.
29. Uekusa Y., Yu WG, Mukai T., et al. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res. 2002 ; 62: 3751-3758.
30. Mellado M., de Ana AM, Moreno MC, Martinez C., Rodriguez-Frade JM A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol. 2001 ; 11: 691-696.